Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Exp Hematol. 2012 Sep 11;41(1):91–101.e4. doi: 10.1016/j.exphem.2012.09.001

Figure 3.

Figure 3

The cAMP, but not cGMP, enhances MK development. (A) To modulate the cAMP pathway, FLC were cultured with TPO and treated daily with forskolin (1 and 5 μM) and PGE1 (1 μM). Cultures were analyzed on day 4 for proliferation (total cell count [i]), percent CD61 expressed (ii), and for counts of CD61+ cells (iii). (B) Expression of PKA-C, VASP, phospho-VASP 157Ser, phospho-VASP 239Ser, and GAPDH (loading control) in MKs. (C) To modulate the cGMP pathway, FLC were cultured with TPO, stimulated daily with ODQ (10 μM), DEA/NO (5 μM), L-NAME (100 μM), and 8-pCPT-cGMP (100 μM), and analyzed on day 4 for total cell counts (i), percent CD61 expressed (ii), and counts of CD61+ cells (iii). (D) Expression of β-sGC, PKG-I, VASP, phospho-VASP 157Ser, phospho-VASP 239Ser, and GAPDH, as loading controls, were evaluated in MKs. *Statistically significant differences compared to control; p < 0.05, n = 6.